Status:
COMPLETED
A Study of Torcetrapib/Atorvastatin vs Atorvastatin Alone or Placebo in Patients With High Cholesterol
Lead Sponsor:
Pfizer
Conditions:
Hyperlipidemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. A study to look at lipid levels in subjects taking the study drug, Atorvastatin alone or placebo.
Detailed Description
For additional information please call: 1-800-718-1021
Eligibility Criteria
Inclusion
- subjects with elevated cholesterol
Exclusion
- Women who are pregnant or lactating, or planning to become pregnant.
- Intolerance to statin therapy resulting in withdrawal
- Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
- Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2006
Estimated Enrollment :
3800 Patients enrolled
Trial Details
Trial ID
NCT00138762
Start Date
July 1 2004
End Date
August 1 2006
Last Update
February 17 2012
Active Locations (154)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mobile, Alabama, United States
2
Pfizer Investigational Site
Mesa, Arizona, United States
3
Pfizer Investigational Site
Oro Valley, Arizona, United States
4
Pfizer Investigational Site
Phoenix, Arizona, United States